Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform. Blue Ledge Capital, Evolution VC Partners, Vice Ventures and Gaingels led the financing. It brings Richmond, Virginia-based Qnovia to $50 million raised since inception. Funds raised by Qnovia support its proprietary inhaled drug delivery platform, the […]
Qnovia
Qnovia wins FDA nod for nicotine inhaler as smoking cessation therapy
Qnovia announced that the FDA cleared its investigational new drug (IND) application for the RespiRx smoking cessation inhaler (QN-01). RespiRx, a drug-device combination product, offers inhalable nicotine replacement therapy (NRT) to assist in the quitting of smoking. IND clearance allows Qnovia to initiate a Phase 1 trial in the U.S. to determine the pharmacokinetics, safety, […]
Qnovia has positive results for inhaled smoking cessation therapy
Qnovia announced positive results from its first-in-human study for the QN-01 inhaled smoking cessation therapy. Richmond, Virginia-based Qnovia develops the RespiRx drug delivery platform that leverages a vibrating mesh nebulizer. CEO Brian Quigley explained the technology to Drug Delivery Business News last year. The company designed the QN-01 therapy to meet the need for safe and effective […]
How Qnovia aims to use inhaled therapeutics for smoking cessation
Led by a former tobacco company executive, Qnovia looks to offer nicotine replacement therapy through inhaled drug delivery. Brian Quigley spent just over 16 years at tobacco giant Altria. During his time there, he ran two U.S. business units, including the smokeless tobacco business. In July 2020, he joined founder and then-CEO at Qnovia (then […]
Qnovia raises $17M Series A for inhaled therapeutics pipeline
Qnovia announced today that it raised $17 million in a Series A financing to support its inhaled therapeutics technologies. Blue Ledge Capital led the offering. DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures also participated. Los Angeles-based Qnovia develops inhaled therapeutics. It focuses on nicotine replacement therapy (NRT) and cardiopulmonary diseases. Qnovia […]
